Allon Starts Trial for Brain Disease
Luke Timmerman1/6/11
Allon Therapeutics, a Vancouver, BC-based developer of drugs for neurological disorders, said today it has started enrolling patients in a pivotal clinical trial of its lead drug candidate. The trial will look at whether Allon’s davunetide offers any benefit for patients with progressive supranuclear palsy (PSP), a rare and deadly brain disease. Allon has also tested this drug’s potential against Alzheimer’s and schizophrenia, as CEO Gordon McCauley described in an interview with Xconomy last April.
